Siran M Koroukian1,2,3, Paul M Bakaki1,3, Phyo Than Htoo1,3, Xiaozhen Han1,3, Mark Schluchter1,2, Cynthia Owusu2,4, Gregory S Cooper2,4, Johnie Rose2,5, Susan A Flocke2,5. 1. Department of Epidemiology and Biostatistics, School of Medicine, Case Western Reserve University, Cleveland, Ohio. 2. Case Comprehensive Cancer Center, Cleveland, Ohio. 3. Population Health and Outcomes Research Core, Clinical and Translational Science Collaborative, Case Western Reserve University, Cleveland, Ohio. 4. Department of Medicine, University Hospitals of Cleveland, School of Medicine, Case Western Reserve University, Cleveland, Ohio. 5. Department of Family and Community Health, School of Medicine, Case Western Reserve University, Cleveland, Ohio.
Abstract
BACKGROUND: As an organized screening program, the national Breast and Cervical Cancer Early Detection Program (BCCEDP) was launched in the early 1990s to improve breast cancer outcomes among underserved women. To analyze the impact of the BCCEDP on breast cancer outcomes in Ohio, this study compared cancer stages and mortality across BCCEDP participants, Medicaid beneficiaries, and "all others." METHODS: This study linked data across the Ohio Cancer Incidence Surveillance System, Medicaid, the BCCEDP database, death certificates, and the US Census and identified 26,426 women aged 40 to 64 years who had been diagnosed with incident invasive breast cancer during the years 2002-2008 (deaths through 2010). The study groups were as follows: BCCEDP participants (1-time or repeat users), Medicaid beneficiaries (women enrolled in Medicaid before their cancer diagnosis [Medicaid/prediagnosis] or around the time of their cancer diagnosis [Medicaid/peridiagnosis]), and all others (women identified as neither BCCEDP participants nor Medicaid beneficiaries). The outcomes included advanced-stage cancer at diagnosis and mortality. A multivariable logistic and survival analysis was conducted to examine the independent association between the BCCEDP and Medicaid status and the outcomes. RESULTS: The percentage of women presenting with advanced-stage disease was highest among women in the Medicaid/peridiagnosis group (63.4%) and lowest among BCCEDP repeat users (38.6%). With adjustments for potential confounders and even in comparison with Medicaid/prediagnosis beneficiaries, those in the Medicaid/peridiagnosis group were twice as likely to be diagnosed with advanced-stage disease (adjusted odds ratio, 2.20; 95% confidence interval, 1.83-2.66). CONCLUSIONS: Medicaid/peridiagnosis women are at particularly high risk to be diagnosed with advanced-stage disease. Efforts to reduce breast cancer disparities must target this group of women before they present to Medicaid. Cancer 2017;123:3097-106.
BACKGROUND: As an organized screening program, the national Breast and Cervical Cancer Early Detection Program (BCCEDP) was launched in the early 1990s to improve breast cancer outcomes among underserved women. To analyze the impact of the BCCEDP on breast cancer outcomes in Ohio, this study compared cancer stages and mortality across BCCEDP participants, Medicaid beneficiaries, and "all others." METHODS: This study linked data across the Ohio Cancer Incidence Surveillance System, Medicaid, the BCCEDP database, death certificates, and the US Census and identified 26,426 women aged 40 to 64 years who had been diagnosed with incident invasive breast cancer during the years 2002-2008 (deaths through 2010). The study groups were as follows: BCCEDP participants (1-time or repeat users), Medicaid beneficiaries (women enrolled in Medicaid before their cancer diagnosis [Medicaid/prediagnosis] or around the time of their cancer diagnosis [Medicaid/peridiagnosis]), and all others (women identified as neither BCCEDP participants nor Medicaid beneficiaries). The outcomes included advanced-stage cancer at diagnosis and mortality. A multivariable logistic and survival analysis was conducted to examine the independent association between the BCCEDP and Medicaid status and the outcomes. RESULTS: The percentage of women presenting with advanced-stage disease was highest among women in the Medicaid/peridiagnosis group (63.4%) and lowest among BCCEDP repeat users (38.6%). With adjustments for potential confounders and even in comparison with Medicaid/prediagnosis beneficiaries, those in the Medicaid/peridiagnosis group were twice as likely to be diagnosed with advanced-stage disease (adjusted odds ratio, 2.20; 95% confidence interval, 1.83-2.66). CONCLUSIONS: Medicaid/peridiagnosis women are at particularly high risk to be diagnosed with advanced-stage disease. Efforts to reduce breast cancer disparities must target this group of women before they present to Medicaid. Cancer 2017;123:3097-106.
Authors: Mary C White; Frances Babcock; Nikki S Hayes; Angela B Mariotto; Faye L Wong; Betsy A Kohler; Hannah K Weir Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: Evaline Xie; Graham A Colditz; Min Lian; Tracy Greever-Rice; Chester Schmaltz; Jill Lucht; Ying Liu Journal: JNCI Cancer Spectr Date: 2022-05-02
Authors: K Robin Yabroff; Katherine Reeder-Hayes; Jingxuan Zhao; Michael T Halpern; Ana Maria Lopez; Leon Bernal-Mizrachi; Anderson B Collier; Joan Neuner; Jonathan Phillips; William Blackstock; Manali Patel Journal: J Natl Cancer Inst Date: 2020-07-01 Impact factor: 13.506
Authors: Neela L Penumarthy; Robert E Goldsby; Stephen C Shiboski; Rosanna Wustrack; Patricia Murphy; Lena E Winestone Journal: Cancer Med Date: 2019-12-15 Impact factor: 4.452